Oncolytic viruses as therapeutic cancer vaccines - Molecular Cancer
Global Therapeutic Vaccines Market 2014 - 2019
-
Upload
mordor-intelligence -
Category
Documents
-
view
217 -
download
1
description
Transcript of Global Therapeutic Vaccines Market 2014 - 2019
GLOBALTHERAPEUTICVACCINES MARKET
Market Shares, Forecasts& Trends
2014 - 2019
mordorintelligence.com
TABLE OF CONTENTS
1. Introduction 1
1.1 Overview 1
1.2 Market Definition 2
1.3 Market Trends 3
2. Executive Summary 4
3. Global Therapeutic Proteins Market – Industry Analysis 5
3.1 Market Drivers 5
3.1.1 Increasing demand ,higher onset of diseases 5
3.1.2 Government funded projects and associations 6
3.1.3 Higher profitability and improved technology 6
3.2 Market opportunities 7
3.2.1 New Target populations- shift from established markets to lesser 8
developed markets
3.3 Market Constraints 9
3.3 .1 Risk of adverse effects 9
3.3.3 High regulatory Intervention and cost 10
4. Types of Vaccines 11
I. Live, attenuated vaccines 11
II. Inactivated vaccines 12
III. Subunit vaccines 13
IV. Toxoid vaccines 14
V. Conjugate vaccines 15
VI. DNA vaccines 16
Global Therapeutic Vaccines Market | Sample
VII. Recombinant vector vaccines 16
5. Vaccine market by application ( Market Size , Forecast, CAGR) 17
5.1 Pediatric Vaccines 17
5.1.1 Pneumococcal 18
5.1.2 Varicella 19
5.1.3 Combinations 20
5.1.3.1 Bivalent 20
5.1.3.2 Trivalent 21
5.1.3.3 Tetravalent 21
5.1.3.4 Pentavalent 22
5.1.4 MMR 23
5.1.5 Poliovirus 24
5.1.6 Hepatitis 25
5.1.7 HIB 26
5.1.8 Other Pediatric 26
5.2 Adult Vaccines 27
5.2.1 Influenza 27
5.2.2 Cervical Cancer 28
5.2.3 Hepatitis 29
5.2.4 Zoster 29
5.2.5 Other adult vaccines 30
6. Regional Analysis of the Vaccine market 31
6.1 North America (Market Size, Forecast and CAGR) 31
6.1.1 USA 31
6.1.2 Canada 32
Global Therapeutic Vaccines Market | Sample
6.1.3 Rest of north America 33
6.2 Europe (Market Size, Forecast and CAGR) 34
6.2.1 Germany 34
6.2.2 France 35
6.2.3 UK 36
6.2.4 Italy 37
6.2.5 Spain 38
6.2.6 Rest of Europe 39
6.3 Asia Pacific (Market Size, Forecast and CAGR) 40
6.3.1 China 40
6.3.2 India 41
6.3.3 Japan 42
6.3.4 Rest of Asia 43
6.4 Rest of the World(Market Size, Forecast and CAGR) 44
7. Competitive Landscape 45
7.1 Current Market trends In Vaccines 45
7.2 Future of Vaccines 46
7.3 Joint Ventures 47
7.4 Mergers and Acquisitions 48
7.5 PentAct HIB, Quinvaxem and the future of Pentavalent vaccines 49
8. Key Company Profiles 50
8.1 SanofiAvnetis 51
8.2 Merck 52
8.3 Glaxosmithkline 53
8.4 Novartis 54
Global Therapeutic Vaccines Market | Sample
8.5 Pfizer 55
8.6 Serum institute 56
9. List Of tables 57
10. List of Figures 58
11. Appendix 59
Global Therapeutic Vaccines Market | Sample
RESEARCH METHODOLOGY
1) Secondary Research: Information was collected from a number of public and paid data sources. Public
sources involved Government websites, publications from the therapeutic vaccine programs of different
countries, company annual reports, white papers and research publications by recognized industry experts, WHO,
Food and drug administration, National cancer Institute, Clinical trials.gov. Paid data sources include authentic
industry databases.
2) Primary Research: After collecting data from secondary sources, primary interviews were conducted with
stakeholders at different points of therapeutic vaccines manufacturers, distributors, ingredient suppliers,
companies manufacturing therapeutic vaccines and key opinion leaders of the industry. 50 respondents
constituting therapeutic vaccines manufacturers, distributors, suppliers, hospital administrators, etc. were
interviewed. The data collected from the survey was analyzed by an expert team of analysts to both validate the
data points obtained from secondary research and to fill any gaps in data.
3) Market Analysis: The market analysis phase involves analyzing the collected data, market breakdown
and forecasting. Macroeconomic indicators and bottom-up and top-down approaches are used to arrive at a
complete set of data points that give way to valuable qualitative and quantitative insights. Each data point is
verified by the process of data triangulation to validate the numbers and arrive at a close estimate.
4) Expert Validation: The market analysis data is verified and validated by a number of experts, both in-
house and external.
5) Report Writing: After the data is curated through the process, our analysts begin to write the report.
Garnering insights from data and forecasts, insights are drawn to visualize the entire business ecosystem in a
single report.
Global Therapeutic Vaccines Market | Sample
Global Therapeutic Vaccines Market | Sample
OVERVIEW
The vaccine market accounts for a relatively small share (2-3%) of the global pharmaceutical market sales.
However, there has been rapid growth over recent years, with the vaccine market quadrupling in value from USD 5
billion in 2000 to almost USD 24 billion in 2013. Once a commodity market with low margins, the vaccines on the
market now include blockbusters and mega blockbusters. New candidates for vaccinating against cancers and
HIV are also projected to hit the magic milestone.
Multinational vaccine companies historically have conducted much of the innovation, research, and development
in the field of vaccine production. They have used significant revenues, global size, and deeper expertise to fund.
The development of new technologies for vaccine development – an expensive and relatively time consuming
process. But Despite the success of vaccines, infectious diseases are still a major cause of illnesses worldwide
and at least 40 major infectious diseases are still uncontrolled by vaccination.
There are currently close 120 new vaccines in the pipeline of various companies across the globe set to hit the
market in the next 5 years to come. In anticipation of this and with the emergence of new target market and
smaller player into the market, the Global vaccine market is set to grow by a CAGR of close to 12.4 % till the year
2020.
Source: Mordor Intelligence Analysis
0
5
10
15
20
25
30
2000 2006 2013
Bill
ion
s
Global Vaccine sales( $ billion)
DATA HIDDEN FROM VIEW
Global Therapeutic Vaccines Market | Sample
MARKET DEFINITION
The vaccine Market is different from any other Commodity Market. Compared to the pharmaceutical market it is
relatively small, although growing fast. The vaccine market is rather concentrated on both supply and demand
sides. It is highly regulated and largely dependent on public purchasers and donor policies. The vaccine market
has very distinct features which increase the complexity of assessing and understanding pricing and
procurement in their context. It is made up of individual markets for individual vaccines or vaccine types, each
with their own specificities, particularly on the supply side.
The vaccine market accounts for a relatively small share (2-3%) of the global pharmaceutical market sales.
However, there has been rapid growth over recent years, with the vaccine market quadrupling in value from USD 5
billion in 2000 to almost USD 24 billion in 2013, according to various sources. The market is expected to grow at a
CAGR of 12.4% till 2020, with the arrival of new preventive, therapeutic and adult vaccines.
The market is dominated by 5 major players with Sanofi Pasteur, GSK, Merck, Pfizer, and Novartis being the top
contenders in the market.
Source: company websites
Global Vaccine Majors
MERCK
Pfizer
Global Therapeutic Vaccines Market | Sample
VACCINE MARKET BY APPLICATION (MARKET SIZE, FORECAST, CAGR)
PEDIATRIC VACCINES
Pneumococcal Vaccines
Pneumococcal disease is caused by Streptococcus pneumoniae, a bacterium that has more than 90 serotypes.
Most serotypes cause disease, but only a few produce the majority of invasive pneumococcal disease. The 10
most common types cause 62% of invasive disease worldwide.
There are two major clinical syndromes of invasive pneumococcal disease: bacteremia, and meningitis. They are
both caused by infection with the same bacteria, but have different manifestations.
Pneumococcal pneumonia is the most common disease caused by pneumococcal infection. Pneumococcal
pneumonia can occur in combination with bacteremia and/or meningitis, or it can occur alone. Isolated
pneumococcal pneumonia is not considered invasive disease but it can be severe. It is estimated that 175,000
cases occur each year in the United States. The incubation period is short (1-3 days). Symptoms include abrupt
onset of fever, shaking chills or rigors, chest pain, cough, shortness of breath, rapid breathing and heart rate, and
weakness. The fatality rate is 5%-7% and may be much higher in the elderly. Pneumococcal disease kills more
people in the United States each year than all other vaccine-preventable diseases combined. An estimated 36,850
cases and 4,250 deaths from invasive pneumococcal diseases (bacteremia and meningitis) occurred in the
United States in 2011.
In 2000, the first pneumococcal conjugate vaccine (PCV) was licensed in the U.S. This vaccine contained seven
serotypes (4, 6B, 9V, 14, 18C, 19F, and 23F) of Streptococcus pneumoniae and became known as PCV7 (Prevnar
by Wyeth, now Pfizer). Ten years later in February 2010, a new 13-valent product was licensed — PCV13 (Prevnar
13, Pfizer) — which added 6 new serotypes (1, 3, 5, 6A, 7F, and 19A). Together, these 13 serotypes account for the
majority of invasive pneumococcal disease (IPD) in the U.S., including serotype 19A, which is the most common
IPD-causing serotype in young children.
Global Therapeutic Vaccines Market | Sample
The Pneumococcal Vaccine market in 2012 was pinned to be close to $ 4 Billion and is estimated to grow to $8.5
billion by the year 2020. This is touted to be the fastest growing vaccine market in the world, forecasted to grow
at a CAGR of 9.62% during the forecasted period.
Table 1: Pneumococcal Vaccine Market ($ millions)
Region 2012 2013 2014 2020 CAGR
NA XX 836 XX XX XX
Europe 1040 XX XX XX XX
APAC XX XX XX 2380 XX
ROW XX XX XX XX 12
Global XX XX XX XX XX
Source: Mordor Intelligence Analysis
Figure 1
Source: Mordor Intelligence analysis
0
1000
2000
3000
4000
5000
6000
7000
8000
9000
2012 2013 2014 2020
$ M
illio
ns
Pneumococcal Vaccines Market
DATA HIDDEN FROM VIEW
Global Therapeutic Vaccines Market | Sample
The Pneumococcal vaccine market is set to grow at a CAGR of 9.62% during the forecasted period. The
APAC regions and the African regions in the Row are bound to see the maximum growth during this
period, due to the increased acceptance and availability of the vaccine in these markets.
Global Therapeutic Vaccines Market | Sample
DISCLAIMER
Mordor Intelligence Reports and their contents, including all the analysis and research containing valuable
market information, are provided to a select group of customers in response to orders. Our customers
acknowledge when ordering that Mordor Intelligence strategic analysis services are for our customers’ internal
use and not for general publication or disclosure to third parties.
Quantitative market information is based primarily on interviews and therefore, is subject to fluctuation. Mordor
Intelligence takes no responsibility for any incorrect information supplied to us by manufacturers or users.
No part of this strategic analysis service may be given, lent, resold or disclosed to non-customers without written
permission. Reproduction and/or transmission in any form and by any means including photocopying,
mechanical, electronic, recording or otherwise, without the permission of the publisher is prohibited.
ABOUT US
Mordor Intelligence is a global market research and consulting firm. Our singular focus is to provide research
insights for business success.
Our research team has expertise in diverse fields like Agriculture, Healthcare, ICT, Chemicals, Manufacturing,
Logistics, Electronics and Automotive. However diverse the expertise maybe, everyone in our team shares one
common trait - we love data and we love providing solutions to clients using that data even more. Seeing your
business flourish based on our solutions and strategy is what we love the most.
For information regarding permissions and sales, please contact: [email protected]
7 | Mordor Intelligence !
!
Mordor Intelligence LLP No. 30, Padma Nilaya, Chola Nagar Bangalore, Karnataka, India 560032
+1 781 881 1110 | [email protected]
Copyright © 2014 Mordor Intelligence LLP All Rights Reserved. This document contains highly confidential information and is the sole property of Mordor Intelligence LLP. No part of it may be circulated, copied, quoted, or otherwise reproduced without the approval of Mordor Intelligence LLP.